Inhibrx Biosciences, Inc. (INBX)
109.35
+4.62
(+4.41%)
USD |
NASDAQ |
Sep 18, 16:00
109.58
+0.23
(+0.21%)
Pre-Market: 20:00
Inhibrx Biosciences Enterprise Value : 1.657B for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 1.657B |
| September 17, 2026 | 1.589B |
| September 16, 2026 | 1.545B |
| September 15, 2026 | 1.602B |
| September 14, 2026 | 1.673B |
| September 11, 2026 | 1.656B |
| September 10, 2026 | 1.687B |
| September 09, 2026 | 1.708B |
| September 08, 2026 | 1.730B |
| September 04, 2026 | 1.831B |
| September 03, 2026 | 1.847B |
| September 02, 2026 | 1.886B |
| September 01, 2026 | 1.882B |
| August 31, 2026 | 1.912B |
| August 28, 2026 | 1.864B |
| August 27, 2026 | 1.871B |
| August 26, 2026 | 1.892B |
| August 25, 2026 | 1.853B |
| August 24, 2026 | 1.592B |
| August 21, 2026 | 1.573B |
| August 20, 2026 | 1.507B |
| August 19, 2026 | 1.541B |
| August 18, 2026 | 1.440B |
| August 17, 2026 | 1.402B |
| August 14, 2026 | 1.348B |
| Date | Value |
|---|---|
| August 13, 2026 | 1.475B |
| August 12, 2026 | 1.495B |
| August 11, 2026 | 1.407B |
| August 10, 2026 | 1.418B |
| August 07, 2026 | 1.352B |
| August 06, 2026 | 1.310B |
| August 05, 2026 | 1.282B |
| August 04, 2026 | 1.277B |
| August 03, 2026 | 1.265B |
| July 31, 2026 | 1.255B |
| July 30, 2026 | 1.295B |
| July 29, 2026 | 1.214B |
| July 28, 2026 | 1.220B |
| July 27, 2026 | 1.261B |
| July 24, 2026 | 1.248B |
| July 23, 2026 | 1.299B |
| July 22, 2026 | 1.312B |
| July 21, 2026 | 1.337B |
| July 20, 2026 | 1.285B |
| July 17, 2026 | 1.334B |
| July 16, 2026 | 1.358B |
| July 15, 2026 | 1.390B |
| July 14, 2026 | 1.419B |
| July 13, 2026 | 1.404B |
| July 10, 2026 | 1.416B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AnaptysBio, Inc. | 1.593B |
| 4D Molecular Therapeutics, Inc. | 518.24M |
| Design Therapeutics, Inc. | 561.25M |
| Agenus, Inc. | 599.19M |
| Amgen, Inc. | 251.80B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -36.65M |
| Total Expenses (Quarterly) | 36.65M |
| EPS Diluted (Quarterly) | -2.339 |
| Earnings Yield | -8.12% |
| Normalized Earnings Yield | -8.117 |